Editorial III. Old dog - New (ma)trix

British Journal of Anaesthesia

Volumn 90, Issue 6, 2003, Pages 722-724

  Budd, Keith ^a   Collet, B J ^b  

^a Leicester Royal Infirmary ^*  (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; BETA FLUNALTREXAMINE; BUPRENORPHINE; DOXAPRAM; DRUG METABOLITE; MORPHINE; NALOXONE; NORBUPRENORPHINE; OPIATE; OPIATE ANTAGONIST; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT;

ANALGESIA; CANCER PAIN; CONSTIPATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EXCRETION; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG TISSUE LEVEL; EDITORIAL; HUMAN; NAUSEA; NONHUMAN; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SUSTAINED RELEASE PREPARATION; TRANSDERMAL PATCH; VOMITING; WITHDRAWAL SYNDROME; DRUG ADMINISTRATION; INTRADERMAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; BUPRENORPHINE; CHEMISTRY, PHYSICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS;

EID: 0038201913     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeg133     Document Type: Editorial

References (31)

1. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569-80
2. Budd K. High dose buprenorphine for postoperative analgesia. Anaesthesia 1981; 36: 900-3
3. Cowan A, Doxey JC, Harry EJR. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977; 60: 547-54
4. Lizosoain I, Leza JC, Lorenzo P. Buprenorphine: bell-shaped dose-response curve for its antagonist effects. Gen Pharmacol 1991; 22: 297-300
5. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatr 1978; 35: 510-6
6. Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274: 361-72
7. Atkinson RE, Schofield P, Mellor P. The efficacy in sequential use of buprenorphine and morphine in advanced cancer pain. In: Doyle D, ed. Opioids in the Treatment of Cancer Pain. London: Royal Society of Medicine, 1990; 81-7
8. Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharm Ther 1989; 45: 66-71
9. Foss JF, O'Connor MF, Yuan C-S, et al. Safety and tolerance of methylnaltrexone in healthy humans: randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol 1997; 37: 25-30
10. Budd K. Buprenorphine. Clin Anaesthesiol 1983; 1: 147-79
11. Chrubasik J, Martin E, Chrubasik S, et al. Epidural buprenorphine. How safe is 'safe'. Acta Anaesthesiol Scand 1994; 38: 525-6
12. Ventafridda V, Conno F, Guarise G, et al. Chronic analgesic study on buprenorphine action in cancer pain. Comparison with pentazocine. Arzneim Forsch 1983; 33: 587-90
13. Bach V, Kamp-Jensen M, Jensen N-H, Eriksen J. Buprenorphine and sustained release morphine - effects and side effects in chronic use. Pain Clin 1991; 4: 87-93
14. Scuderi PE, James RL, Harris L. Multimodal antiemetic management prevents early postoperative vomiting after outpatient laparoscopy. Anesth Analg 2000; 91: 1408-14
15. Zaki PA, Keith DE, Brine GA, et al. Ligand-induced changes in surface μ-opioid receptor number: relationship to G protein activity? J Pharmacol Exp Ther 2000; 292: 1127-34
16. Jasinski DA, Pevnick JS, Griffith JD. Buprenorphine: a potential agent for treating narcotics addiction. Fed Proc 1977; 36: 1025-34
17. Lange WR, Fudala PJ, Dax EM, Rolley EJ. Safety and side effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend 1997; 45: 81-91
18. Walter DS, Inturrisi CE. Absorption, distribution, metabolism and excretion of buprenorphine in animals and humans. In: Cowan A, Lewis JW, eds. Buprenorphine: Combating Drug Abuse with a Unique Opioid. New York: Wiley Liss Inc., 1995; 113-35
19. McQuay HJ, Moore RA. Buprenorphine: kinetics in humans. In: Cowan A, Lewis JW, eds. Buprenorphine: Combating Drug Abuse with a Unique Opioid. New York: Wiley Liss Inc., 1955; 137-50
20. Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997; 281: 428-33
21. Transtec Product Monograph. Cambridge: Napp Pharmaceuticals Ltd, 2002
22. Data held on file. Aachen: Grunenthal GmbH, 2002
23. Jeal W, Benfield P. Transdermal fentanyl. Drugs 1997; 53: 109-38
24. Scott DHT, Arthur GR, Scott DB. Haemodynamic changes following buprenorphine and morphine. Anaesthesia 1980; 35: 957-61
25. Budd K. Immunosuppressive effects induced by opioid analgesics. International Monitor on Regional Anaesthesia and Pain Management 2002; 14: 3-7
26. Atkinson RE. Medicolegal aspects of pain management. Pain Rev 2000; 7: 25-36
27. Buckoms AJ, Masand P, Murray GB, et al. Chronic nonmalignant pain treated with long-term oral narcotic analgesics. Ann Clin Psychiatr 1992; 4: 185-92
28. Portnoy RK. Opioid therapy for chronic nonmalignant pain: current status. In: Fields HL, Liebeskind JC, eds. Progress in Pain Research and Management Vol I. Seattle: IASP Press, 1994; 247-87
29. McCormack K. Signal transduction in neuropathic pain, with special emphasis on the analgesic role of opioids - Part II: moving basic science towards a new pharmacotherapy. Pain Rev 1999; 6: 99-131
30. Omote K, Ohmorii H, Kawamata M, et al. Intrathecal buprenorphine in the treatment of phantom limb pain. Anesth Analg 1995; 80: 1030-2
31. Evans PDJ. Opioids for chronic musculoskeletal pain. In: Kalso E, McQuay HJ, Wiesenfeld-Hallin Z, eds. Opioid Sensitivity of Chronic Noncancer Pain. Seattle: IASP Press, 1999; 349-65